Bristol-Myers Squibb Company (BMY) Stock: Price, Forecast & Analyst Target
Bristol-Myers Squibb Company (BMY) — MoonshotScore 91/100 (Exceptional band), calculated Oct 6, 2026. Price $58.81 (-3.83%), as of the Oct 5, 2026 trading session; market cap $120B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Bristol-Myers Squibb Company · BMY · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Bristol Myers Squibb develops, licenses and commercializes medicines across oncology, hematology, cardiovascular care, immunology and neuroscience, with Eliquis and Opdivo anchoring product revenue. Its equity story depends on whether the wider portfolio can counter the contraction embedded in longer-range revenue expectations without weakening cash generation.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Bristol-Myers Squibb Company (BMY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, at a cheap price, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $12.97B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- expected results Oct 29, 2026
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
The score moved from 92 in the stored Oct 5, 2026 snapshot to 91 in the current publication computed Oct 6, 2026 (-1); the largest pillar moves were Momentum -4 and Valuation +2. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $58.81 | |
| Change on the day | -3.83% | |
| 52-week range | $42.52–$68.64 | |
| Market capitalisation | $120B | |
| Price / earnings (trailing) | 12.95 | |
| Shares traded on the day | 19.24M | |
| Beta (volatility vs the S&P 500) | 0.23 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Bristol-Myers Squibb Company (BMY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the BMY film — every key number, told as a short cinematic story
~2 min · open the film
What is Bristol-Myers Squibb Company (BMY), and what does it report?
Short answer · as of
Bristol Myers Squibb sells medicines rather than generalized healthcare services.
Research dated 2026-09-12.
Bristol Myers Squibb sells medicines rather than generalized healthcare services. Demand comes from the use of therapies such as Eliquis for clot and stroke prevention, Opdivo and Yervoy for cancer, Orencia for inflammatory disease, and Breyanzi for eligible lymphoma patients; distribution runs through wholesalers, pharmacies, hospitals, clinics and government organizations.
Reported revenue therefore measures a commercial drug portfolio with sharply different indications and treatment settings. Eliquis and Opdivo dominate the disclosed product view, while Orencia, Revlimid and Yervoy contribute smaller streams, so consolidated growth can conceal meaningful changes in the product mix.
What do the latest results show for Bristol-Myers Squibb Company (BMY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $12.97B.
Research dated 2026-09-12.
Revenue rebounded in the latest period and exceeded the recent range. Gross profit, operating income and net income rose more sharply than sales, while research spending also increased, showing stronger profit conversion without a retreat from development expense.
The earnings history shows an uninterrupted run of revenue and earnings results above consensus. That is an expectations observation rather than evidence of smooth underlying growth: annual revenue recently changed little while net income swung from a large loss to a substantial profit, and quarterly cash generation has remained uneven.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $12.97B | $3.32B | $1.62 (diluted) |
| Q1 FY2026 | $11.49B | $2.68B | $1.31 (diluted) |
| Q4 FY2025 | $12.50B | $1.09B | $0.53 (diluted) |
| Q3 FY2025 | $12.22B | $2.20B | $1.08 (diluted) |
What are the financial strengths and risks for Bristol-Myers Squibb Company (BMY)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operations have generated positive cash throughout the reported quarterly series, with capital spending consuming a modest share of that inflow. Short-term liquidity covers near-term obligations, and the latest cash balance improved from the prior period.
Debt remains far above cash and investments, leaving Bristol Myers Squibb in a substantial net-debt position. The company-specific vulnerability is that Eliquis and Opdivo carry much of the disclosed product base; erosion in those franchises would have to be absorbed by other medicines while research spending and debt claims continue. Longer-range revenue estimates indicate that this replacement burden is already central to market expectations.
What should you watch next at Bristol-Myers Squibb Company (BMY)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-12.
At the scheduled earnings release, watch whether revenue remains near its latest high, whether gross profit continues to translate into operating income, and whether reported revenue and earnings again clear consensus. Research spending also deserves attention because the latest advance in profitability occurred alongside a higher development outlay.
Beyond the headline result, the useful test is product substitution: gains outside Eliquis and Opdivo need to become large enough to change the declining path embedded in longer-range estimates. Cash conversion should confirm the accounting result, while movement in cash relative to debt will show whether operating strength is improving financial flexibility.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Bristol-Myers Squibb Company compare with its peers?
Short answer
Bristol-Myers Squibb Company's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Bristol Myers Squibb belongs with commercial biopharmaceutical portfolios rather than businesses valued mainly on research prospects. Its mix combines a major anticoagulant franchise, broad oncology medicines, immunology and hematology products, and an autologous cell therapy, supported by established revenue and operating cash flow.
Therapeutic breadth does not produce balanced economics. Eliquis and Opdivo still dominate disclosed product revenue, making Bristol Myers Squibb less a collection of equally weighted franchises than a mature commercial base funding the search for its eventual replacements.
| Company | Price | Market value | Score |
|---|---|---|---|
| $503.50 Oct 5, 2026 | $128B | 97 5-pillar Oct 6, 2026 | |
| $1143.12 Oct 5, 2026 | $1.08T | 97 5-pillar Oct 6, 2026 | |
| Bristol-Myers Squibb Company (BMY) — this page | $58.81 | $120B | 91 |
| $252.93 Oct 5, 2026 | $610B | 90 5-pillar Oct 6, 2026 | |
| $46.55 Oct 5, 2026 | $93.3B | 88 5-pillar Oct 6, 2026 | |
| $402.98 Oct 5, 2026 | $217B | 85 5-pillar Oct 6, 2026 | |
| $156.53 Oct 5, 2026 | $242B | 85 5-pillar Oct 6, 2026 | |
| $140.93 Oct 5, 2026 | $267B | 84 5-pillar Oct 6, 2026 | |
| $39.51 Oct 5, 2026 | $94.9B | 83 5-pillar Oct 6, 2026 | |
| $265.76 Oct 5, 2026 | $470B | 78 5-pillar Oct 6, 2026 | |
| $139.54 Oct 5, 2026 | $345B | 74 5-pillar Oct 6, 2026 | |
| $87.01 Oct 5, 2026 | $111B | 70 5-pillar Oct 6, 2026 | |
| $27.41 Oct 5, 2026 | $156B | 68 5-pillar Oct 6, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $59.00 – $82.00
- Consensus target
- $69.22
- Median target
- $65.00
Consensus record · Captured .
Measured against a quoted price of $58.81 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 2, 2026
- Transactions
- 33
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 2
- Other transactions
- 31
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Bristol-Myers Squibb Company (BMY)?
Common Questions About BMY (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How dependent is Bristol Myers Squibb on Eliquis and Opdivo?
Eliquis and Opdivo are the dominant disclosed product revenue streams. Their scale gives Bristol Myers Squibb a large commercial base, but it also means weakness in either franchise would require meaningful offsets from the rest of the portfolio.
Can Breyanzi change Bristol Myers Squibb's business mix?
Breyanzi gives Bristol Myers Squibb exposure to autologous cell therapy for eligible lymphoma patients. The disclosed revenue mix remains led by Eliquis and Opdivo, so a broader economic shift would require specialty therapies such as Breyanzi to become much more consequential within the portfolio.
Why do Bristol Myers Squibb earnings move more than revenue?
Annual revenue recently remained nearly level while net income moved from a large loss to a substantial profit, and quarterly profit has also fluctuated more than sales. Research and commercial spending are large enough that changes below the revenue line can materially alter reported earnings.
What would improve Bristol Myers Squibb's declining revenue outlook?
Sustained growth from medicines outside Eliquis and Opdivo would need to offset pressure on the leading franchises. Confirmation would appear as a less concentrated product mix, resilient consolidated sales and continued cash generation despite ongoing research spending.
What is the BMY stock price today?
The last price recorded on this page for Bristol-Myers Squibb Company (BMY) is $58.81, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BMY price target?
The analyst consensus price target for Bristol-Myers Squibb Company (BMY) is $69.22 (range $59.00 to $82.00, median $65.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are BMY's next earnings?
The next earnings date listed on this page for Bristol-Myers Squibb Company (BMY) is Oct 29, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (26 figures)
The 26 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Route 206 AND Province Line Road, Princeton, NJ, 08543 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Route 206 & Province Line Road, Princeton, NJ, 08543, US". The FMP company description names New York, New York as the headquarters; this page uses the address in this row. |
FMP — 21 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $58.81 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T11:44:45.579Z. | |
px.change | Change on the day | -3.83% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $120B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-06. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$2.34 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $12.97B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $42.52–$68.64 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 12.95 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 19.24M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.23 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Christopher Boerner | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 32,500 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY1970 through FY2025: FY1970 revenue $0.00, net result $0.00; FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 71.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 5.38× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt_range | Analyst price target, low to high | $59.00 – $82.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $69.22 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 33 transactions · 0 purchases, 2 sales, 31 other transactions · 11 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 2, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-09-14 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-18 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 91 of 100 · Exceptional · pillars 95 / 52 / 73 / 86 / 75 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 92 (stored snapshot Oct 5, 2026) → 91 (current publication computed Oct 6, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Opdivo: $10.05B; Yervoy: $2.90B; Eliquis: $14.44B; Orencia: $3.71B; Revlimid: $2.95B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-30 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash, investments and debt | Total debt: $43.12B; Liquidity basis: cash and short-term investments; Total liabilities: $65.31B; Cash and short-term investments: $11.07B; Cash and investments: $11.46B; Long-term investments: $397.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $11.46B; Cash and short-term investments: $11.07B; Long-term investments: $397.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$32.05B; Total debt: $43.12B; Cash and investments: $11.07B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.38; Current ratio: 1.53; Debt to equity: 1.93; Net margin: 18.9%; Gross margin: 70.2%; Operating margin: 28.3%; Return on assets: 10.6%; Return on equity: 46.8% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-29; EPS estimate: $1.68 per share; Revenue estimate: $12.59B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.
ETFs that hold BMY
Funds in our ETF coverage that list BMY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 5.36% | |
| Brookstone Value Stock ETF (BAMV) | 4.41% | |
| Alger Russell Innovation ETF (INVN) | 2.71% | |
| WisdomTree U.S. High Dividend Fund (DHS) | 2.51% | |
| Pacer US Cash Cows 100 ETF (COWZ) | 2.21% | |
| SPDV ETF | 2.05% | |
| UVA Dividend Value ETF (UVDV) | 1.72% |